[Multicenter study of cefoperazone in Austria].
109 patients entered a multicentre study for treatment with Cefoperazone of respiratory, urogenital, and hepato-biliary tract infections, as well as peritonitis. The purpose of the study was to determine the efficacy, tolerance as well as the therapeutic advantages of a new agent of the group of betalactam-antibiotics which is excreted by the liver with the bile and--to a far lesser extent--by the kidneys. The mean duration of therapy was 7.2 days. The mean dosage was 2 g twice a day. Efficacy and tolerance of Cefoperazone were excellent.